Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotech company, has announced the commencement of trading on the Nasdaq under the ticker symbol ‘EPRX’. The company, known for its proprietary Diffusphere™ technology, aims to improve drug delivery in areas with high unmet medical needs. Its lead product candidate, EP-104IAR, has shown promise in a Phase 2b clinical trial for knee osteoarthritis pain treatment, and it is also exploring applications for gastrointestinal diseases and other conditions.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
